Harbour BioMed Announces 2023 Interim Results
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Aug. 28, 2023 /PRNewswire/ -- Harbour BioMed ("HBM", or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunology, today announced its interim results for the six months ended June 30, 2023....
Israel Honors Pfizer CEO Albert Bourla with the “Jewish Nobel” Prize
Bourla donates his $1 million Genesis Prize award towards the construction of the Holocaust Museum of Greece in Thessaloniki, to commemorate Greek-Jewish communities wiped out by the Nazis JERUSALEM, June 30, 2022 /PRNewswire/ -- Today the President of Israel Isaac Herzog presented the Genesis Prize to Dr. Albert Bourla at a ceremony in Israel's capital Jerusalem. President...
Alphamab Oncology Announces IND Application for Innovative PD-L1/ VEGFR2 Bispecific ADC JSKN027 was Officially Accepted by CDE
SUZHOU, China, Dec. 18, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the Investigational New Drug (IND) application for JSKN027, an independently developed innovative bispecific antibody-drug conjugate (ADC) targeting PD-L1 and VEGFR2, has been officially accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). The Company plans to initiate a clinical...
TES Pharma Congratulates Intercept Pharmaceuticals on their Presentation of Phase 1 INT-787 Data at the AASLD Meeting and the Initiation of the Phase 2a FRESH Study in Patients with...
INT-787 is a selective next generation FXR agonist invented by TES Pharma and licensed to Intercept Pharmaceuticals INT-787 has shown strong anti-fibrotic and anti-inflammatory effects in animal models TES Pharma is dedicated to the identification of novel therapeutic targets and the discovery and development of new molecules to efficiently address the needs...
WuXi AppTec Continued Solid Growth in the First Three Quarters of 2023 on Top of an Exceptionally Strong Year in 2022, with Profit Growth Continuously Exceeding Revenue Growth
Revenue of RMB10,670 Million in the Third Quarter, Single Quarter Revenue Back to over RMB10 Billion; Revenue of RMB29,541 Million in the First Three Quarters, Up 4.0% Year-over-Year; Excluding COVID-19 Commercial Projects, Up 23.4% Net Profit Attributable to Owners of the Company for the First Three Quarters Increased 9.5% to RMB8,076 Million; Diluted Earnings per Share (EPS) Increased...
Transcenta to Participate in Four Upcoming Conferences
SUZHOU, China, Oct. 24, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical-stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development, and manufacturing of antibody-based therapeutics, announces that the management team will participate in four upcoming investor conferences in October and November 2022 as follows: 1) 2022 Listed Companies Roadshow Conference* Season 3 (Pharmaceutical and Biological Industry)...
PolyU startup iMeddy provides free video medical consultation to COVID-19 patients to help fight the pandemic leveraging innovative technology
HONG KONG, March 24, 2022 /PRNewswire/ -- Amid the severity of the fifth wave of the COVID-19 pandemic, a startup nurtured by The Hong Kong Polytechnic University (PolyU), known as iMeddy, is providing a free video medical consultation service on its pioneering online healthcare platform to a quota of 3,000 COVID-19 patients. The service is supported by an aggregate...
Diagnostic Imaging for Women Enhances Mammography Quality with AI: Results Presented at ASMIRT 2024
DARWIN, Australia, May 10, 2024 /PRNewswire/ -- At the Australian Society of Medical Imaging and Radiation Therapy (ASMIRT) conference this week in Darwin, Diagnostic Imaging for Women (difw), together with Volpara Health announced significant advancements in applying AI to mammography quality assurance. Over a 12-month period, the application of Volpara Analytics™...
Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study for Ovarian Cancer of Anti-HER2 Bispecific ADC JSKN003
SUZHOU, China, Feb. 13, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-306) of anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003. The study aims to compare the efficacy of JSKN003 versus investigator-selected chemotherapy for the treatment of platinum-resistant recurrent epithelial ovarian cancer, primary...
GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO COMMUNITY LED INITIATIVES IN HONG...
-- Gilead Awards US$4 Million Globally (Excluding the United States) Through The Gilead ALL4LIVER Grant -- -- World Hepatitis Alliance Supports Global Expansion of Gilead ALL4LIVER Grant by Joining Grant Review Committee -- -- Hong Kong Liver Foundation and Hong Kong Liver Transplant Patients' Association Receive The Grant to Launch Innovative...
